Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Dimitri E. Grigoriadis net worth and biography

Dimitri Grigoriadis Biography and Net Worth

Insider of Neurocrine Biosciences

Dimitri E. Grigoriadis, Ph.D. was appointed Chief Research Officer in 2013. Dr. Grigoriadis oversees all research functions, including drug discovery, biology, and chemistry, and has led such functions since 2006. Dr. Grigoriadis joined Neurocrine Biosciences in 1993, established the pharmacology and drug screening groups and was most recently a Neurocrine Biosciences Fellow and Vice President of Discovery Biology. Prior to joining Neurocrine Biosciences, he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993. Dr. Grigoriadis received his B.Sc. from the University of Guelph in Ontario, Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse from 1987 to 1990.

What is Dimitri E. Grigoriadis' net worth?: The estimated net worth of Dimitri E. Grigoriadis is at least $14.18 million as of May 7th, 2020. Dr. Grigoriadis owns 104,741 shares of Neurocrine Biosciences stock worth more than $14,184,026 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Grigoriadis may own. Learn More about Dimitri E. Grigoriadis' net worth.
How do I contact Dimitri E. Grigoriadis?: The corporate mailing address for Dr. Grigoriadis and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Dimitri E. Grigoriadis' contact information.
Has Dimitri E. Grigoriadis been buying or selling shares of Neurocrine Biosciences?: Dimitri E. Grigoriadis has not been actively trading shares of Neurocrine Biosciences during the last quarter. Most recently, Dimitri E. Grigoriadis sold 8,000 shares of the business's stock in a transaction on Thursday, October 7th. The shares were sold at an average price of $104.81, for a transaction totalling $838,480.00. Learn More on Dimitri E. Grigoriadis' trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 44 times. They sold a total of 542,972 shares worth more than $74,251,850.99. The most recent insider tranaction occured on December, 17th when insider Ingrid Delaet sold 1,091 shares worth more than $147,285.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 12/17/2024.

Dimitri E. Grigoriadis Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2021	Sell	8,000	$104.81	$838,480.00
5/7/2020	Sell	8,682	$105.44	$915,430.08	104,741
11/18/2019	Sell	5,000	$115.98	$579,900.00	113,408
11/1/2019	Sell	10,188	$100.34	$1,022,263.92	118,596
8/1/2018	Sell	23,022	$110.00	$2,532,420.00
6/20/2018	Sell	23,000	$105.00	$2,415,000.00	105,942
6/14/2018	Sell	86,963	$99.48	$8,651,079.24	146,905
2/12/2018	Sell	86,368	$78.32	$6,764,341.76	154,717
2/9/2018	Sell	71,775	$77.98	$5,597,014.50	154,717
11/8/2017	Sell	30,000	$74.58	$2,237,400.00	77,691
8/9/2017	Sell	15,354	$55.00	$844,470.00	123,045
5/23/2017	Sell	10,000	$53.39	$533,900.00	107,691
5/2/2017	Sell	10,000	$55.00	$550,000.00	117,691
2/6/2017	Sell	727	$43.13	$31,355.51	115,756
11/27/2015	Sell	10,000	$57.50	$575,000.00	105,308
7/20/2015	Sell	19,646	$55.00	$1,080,530.00
7/13/2015	Sell	10,000	$50.00	$500,000.00
2/10/2015	Sell	20,000	$35.00	$700,000.00
1/8/2015	Sell	30,000	$27.35	$820,500.00
1/5/2015	Sell	2,500	$22.76	$56,900.00
12/15/2014	Sell	12,794	$22.35	$285,945.90
6/21/2013	Sell	46,837	$12.51	$585,930.87

Dimitri E. Grigoriadis Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.42

$134.12

$137.01

50 Day Range

MA: $123.99

$115.08

$136.69

2 Week Range

Now: $135.42

$110.95

$157.98

Volume

2,265,589 shs

Average Volume

884,102 shs

Market Capitalization

$13.71 billion

P/E Ratio

36.31

Dividend Yield

N/A

Beta

0.34